India Eyes a Role in the Global Brain–Computer Interface Race

The Observer Research Foundation has published a policy brief arguing that India must act on brain–computer interface (BCI) regulation and research investment if it wants to shape, rather than import, the next decade of neurotechnology.

That is the top-line framing from ORF Online, which positions the field as a competitive race among established programs in the United States, China, and parts of Europe. For clinical neurophysiologists, the policy framing matters because scalp EEG remains the dominant signal source for non-invasive BCI prototypes and for the consumer-facing neurotechnology products now reaching Indian clinics and research laboratories.

What does the BCI race look like from a neurophysiology reading room?

BCI systems translate brain signals — most often EEG recorded at the scalp, with smaller cohorts using intracranial EEG (iEEG) or electrocorticography (ECoG) — into commands for external devices. The field spans investigational cortical implants moving through first-in-human trials and scalp-EEG-based systems for communication and motor rehabilitation, which remain the most clinically validated category to date.

The ORF brief situates India against that backdrop. The country has long invested in EEG training and medical-device manufacturing, yet, the argument runs, it lacks a consolidated national neurotechnology strategy. For a monitoring-unit technologist or an EEG lab director, the operational consequence is straightforward: most BCI-grade signal acquisition still happens in academic settings. Regulatory pathways for deploying BCI-assisted rehabilitation outside those settings remain unsettled.

Why does the "India window" matter for practitioners?

A national strategy would change three things at the lab bench:

• Device specifications. Clinical-grade EEG hardware — high-density caps, dry-electrode arrays, hospital-grade amplifiers — is largely imported, which keeps per-unit costs high. Local manufacturing could in principle compress those costs, although the brief does not provide a per-unit comparison.
• Reimbursement. Without a defined clinical indication, hospitals cannot bill for BCI-assisted therapy sessions, which limits routine adoption.
• Training pipelines. The technicians who will run BCI calibration sessions need new competencies in artifact rejection, machine-learning feature review, and closed-loop stimulation protocols.

What stays investigational, what moves toward the clinic?

For the EEG Signal audience, the cleanest distinction is between human data and animal data, and between cleared devices and investigational work. Translation to routine clinical practice requires multicenter trials with predefined endpoints — the kind of infrastructure a coordinated national program could accelerate.

Most peer-reviewed BCI trials report single-digit or low-double-digit enrolment, with motor-restoration and communication cohorts the most common. India's published cohorts sit in that same range, and the brief frames scaling them as both a gap and an opportunity.

Practitioners reading the ORF piece should treat it as a policy signal, not a clinical update. The next concrete step — likely a draft national neurotechnology framework or the formation of an inter-ministerial working group — will indicate whether India intends to be a buyer of BCI platforms or a co-developer.

What changes for the reading room?

For now, nothing immediate. No new EEG montage, no revised acquisition standard, no new clinical practice guideline flows from this brief. But the policy direction will determine which BCI systems Indian neurology and rehabilitation departments can adopt, at what cost, and under which regulatory guardrails.

For departments already running high-density EEG for epilepsy localization, the first operational question is whether reimbursement codes will recognize extended BCI-assisted sessions. Indian regulators currently treat most BCI hardware as research equipment rather than medical devices, so no premarket review pathway comparable to the FDA's 510(k) or de novo route applies. Any national strategy will need to decide whether BCI-assisted rehabilitation falls under existing medical-device rules, neurological-device rules, or requires an entirely new category.

Practitioners who sit on hospital procurement committees, or who train the next cohort of EEG technologists, have a window of their own to comment on that framework before it hardens into procurement law.